Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Rybelsus (semaglutide) is an oral medication used in combination with exercise and a healthy diet to help treat type 2 diabetes. It’s best taken on an empty stomach but isn’t known to interact ...

Rybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution.

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Rybelsus ® reduced major adverse cardiovascular ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic ... s application for a label extension for Rybelsus to reduce the risk of major adverse ...

Medically reviewed by Sohaib Imtiaz, MD Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat ...

in the Rybelsus ® and placebo arms 1. In a key secondary analysis from SOUL published simultaneously, oral semaglutide reduced risk of MACE independently of baseline use of SGLT2i and suggests ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the ...